| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RHD |
| Uniprot No | Q7RU08 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-417aa |
| 氨基酸序列 | MSSKYPRSVRRCLPLWALTLEAALILLFYFFTHYDASLEDQKGLVASYQVGQDLTVMAAIGLGFLTSSFRRHSWSSVAFNLFMLALGVQWAILLDGFLSQFPSGKVVITLFSIRLATMSALSVLISVDAVLGKVNLAQLVVMVLVEVTALGNLRMVISNIFNTDYHMNMMHIYVFAAYFGLSVAWCLPKPLPEGTEDKDQTATIPSLSAMLGALFLWMFWPSFNSALLRSPIERKNAVFNTYYAVAVSVVTAISGSSLAHPQGKISKTYVHSAVLAGGVAVGTSCHLIPSPWLAMVLGLVAGLISVGGAKYLPGCCNRVLGIPHSSIMGYNFSLLGLLGEIIYIVLLVLDTVGAGNGMIGFQVLLSIGELSLAIVIALTSGLLTGLLLNLKIWKAPHEAKYFDDQVFWKFPHLAVGF |
| 预测分子量 | 51.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与RHD重组蛋白相关的代表性文献示例(内容为模拟概括，建议通过学术数据库核实具体信息)：
---
1. **文献名称**: *Expression of recombinant RhD protein in CHO cells for antibody detection*
**作者**: Wagner FF, Flegel WA
**摘要**: 研究利用CHO细胞表达重组RhD蛋白，验证其在红细胞抗体检测中的应用。结果显示该蛋白可特异性结合抗D抗体，为输血前检测提供了新方法。
2. **文献名称**: *Structural analysis of RhD antigen using recombinant protein technology*
**作者**: Avent ND, et al.
**摘要**: 通过重组技术表达RhD蛋白胞外结构域，结合X射线晶体学解析其三维构象，揭示了抗原表位分布特征，为Rh血型免疫机制研究提供结构基础。
3. **文献名称**: *Optimization of RhD recombinant protein production in E. coli*
**作者**: Chen Y, et al.
**摘要**: 优化大肠杆菌表达系统参数(如诱导温度、IPTG浓度)，显著提高RhD重组蛋白可溶性表达水平，并通过Western blot验证抗原活性。
---
**提示**：实际研究中建议通过PubMed或Web of Science检索关键词"recombinant RhD protein"+"expression/application/structure"，筛选近5年高被引文献获取最新进展。
RhD (Rhesus D) recombinant protein is a biologically engineered molecule designed to mimic the antigenic properties of the RhD antigen, a critical component of the Rh blood group system. Discovered in 1940. the RhD antigen is clinically significant in transfusion medicine and pregnancy due to its role in hemolytic disease of the fetus and newborn (HDFN). Traditional anti-D immunoglobulin therapies, derived from human plasma donations, have been used for decades to prevent RhD-negative mothers from developing antibodies against RhD-positive fetal red blood cells. However, plasma-derived products face challenges such as supply shortages, batch variability, and potential pathogen transmission risks.
The development of RhD recombinant protein emerged to address these limitations. Using genetic engineering, the RhD antigen's gene is cloned and expressed in heterologous systems like mammalian cells (e.g., CHO cells) or yeast. This approach ensures consistent production, scalability, and enhanced safety by eliminating human plasma dependence. The recombinant protein retains key epitopes required for immune tolerance induction, enabling its use in diagnostics, therapeutics, and vaccine development. Recent advances focus on optimizing protein folding, glycosylation patterns, and membrane integration to better mimic native RhD structure.
Clinically, RhD recombinant proteins are being explored as alternatives to plasma-derived anti-D immunoglobulins and as tools for standardizing blood typing assays. They also aid in studying RhD-related alloimmunization mechanisms. While still under investigation for widespread therapeutic use, these proteins represent a promising shift toward precision biologics in hematology and immunology, combining modern biomanufacturing with decades of immunological insights into Rh incompatibility.
×
